Genotype does not predict severity of behavioural phenotype in juvenile neuronal ceroid lipofuscinosis (Batten disease)
- PMID: 20187884
- PMCID: PMC2895016
- DOI: 10.1111/j.1469-8749.2010.03628.x
Genotype does not predict severity of behavioural phenotype in juvenile neuronal ceroid lipofuscinosis (Batten disease)
Erratum in
- Dev Med Child Neurol. 2010 Oct;52(10):890
Abstract
Aim: The primary aim of this investigation was to examine genotype and clinical phenotype differences in individuals with juvenile neuronal ceroid lipofuscinosis (JNCL) who were homozygous for a common disease-causing deletion or compound heterozygous. The secondary aim was to cross-validate the Child Behavior Checklist (CBCL) and the Unified Batten Disease Rating Scale (UBDRS), a disease-specific JNCL rating scale.
Method: Sixty individuals (28 males, 32 females; mean age 15y 1mo, SD 4y 9mo, range 5y 8mo--31y 1mo) with JNCL completed the UBDRS.
Results: No significant genotype and clinical phenotype differences were identified when comparing individuals homozygous for the deletion with a heterogeneous group of compound heterozygous individuals. There were significant correlations among related behaviour items and scales on the CBCL and UBDRS (Spearman's rho ranging from 0.39 [p<0.05] to 0.72 [p<0.01]). Behaviour and physical function ratings were uncorrelated, supporting divergent validity of these two constructs in JNCL.
Interpretation: Previous reports of genotype and clinical phenotype differences were unsupported in this investigation, which did not find differences between individuals homozygous or heterozygous for the CLN3 deletion. The CBCL, an already validated measure of behaviour problems, appears valid for use in JNCL and cross-validates well with the UBDRS.
Figures
Similar articles
-
The Unified Batten Disease Rating Scale (UBDRS): Validation and reliability in an independent CLN3 disease sample.Eur J Paediatr Neurol. 2022 May;38:62-65. doi: 10.1016/j.ejpn.2022.03.005. Epub 2022 Apr 4. Eur J Paediatr Neurol. 2022. PMID: 35427884 Free PMC article.
-
Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease).Neurology. 2011 Nov 15;77(20):1801-7. doi: 10.1212/WNL.0b013e318237f649. Epub 2011 Oct 19. Neurology. 2011. PMID: 22013180 Free PMC article.
-
Methodology of clinical research in rare diseases: development of a research program in juvenile neuronal ceroid lipofuscinosis (JNCL) via creation of a patient registry and collaboration with patient advocates.Contemp Clin Trials. 2013 Jul;35(2):48-54. doi: 10.1016/j.cct.2013.04.004. Epub 2013 Apr 26. Contemp Clin Trials. 2013. PMID: 23628560 Free PMC article.
-
Atypical late infantile and juvenile forms of neuronal ceroid lipofuscinosis and their diagnostic difficulties.Folia Neuropathol. 1997;35(2):73-9. Folia Neuropathol. 1997. PMID: 9377079 Review.
-
[From gene to disease; from CLN1, CLN2 and CLN3 to neuronal ceroid lipofuscinosis].Ned Tijdschr Geneeskd. 2005 Feb 5;149(6):300-3. Ned Tijdschr Geneeskd. 2005. PMID: 15730038 Review. Dutch.
Cited by
-
Towards Understanding Behaviour and Emotions of Children with CLN3 Disease (Batten Disease): Patterns, Problems and Support for Child and Family.Int J Environ Res Public Health. 2022 May 12;19(10):5895. doi: 10.3390/ijerph19105895. Int J Environ Res Public Health. 2022. PMID: 35627432 Free PMC article.
-
Analysis of potential biomarkers and modifier genes affecting the clinical course of CLN3 disease.Mol Med. 2011;17(11-12):1253-61. doi: 10.2119/molmed.2010.00241. Epub 2011 Aug 18. Mol Med. 2011. PMID: 21863212 Free PMC article.
-
Reliability and validity of the Wolfram Unified Rating Scale (WURS).Orphanet J Rare Dis. 2012 Nov 14;7:89. doi: 10.1186/1750-1172-7-89. Orphanet J Rare Dis. 2012. PMID: 23148655 Free PMC article.
-
Cardiac magnetic resonance findings in neuronal ceroid lipofuscinosis: A case report.Front Neurol. 2022 Aug 22;13:942667. doi: 10.3389/fneur.2022.942667. eCollection 2022. Front Neurol. 2022. PMID: 36071899 Free PMC article.
-
The c.1A > C start codon mutation in CLN3 is associated with a protracted disease course.JIMD Rep. 2020 Feb 7;52(1):23-27. doi: 10.1002/jmd2.12097. eCollection 2020 Mar. JIMD Rep. 2020. PMID: 32154056 Free PMC article.
References
-
- Boustany R-M. Batten disease or neuronal ceroid lipofuscinosis. In: Moser HW, editor. Handbook of Clinical Neurology. Elsevier Science; Amsterdam: 1996. pp. 671–700.
-
- Santavuori P, Lauronen L, Kirveskari E, Åberg L, Sainio K, Autti T. Neuronal ceroid lipofuscinoses in childhood. Neurol Sci. 2000;21(Suppl 3):S35–41. - PubMed
-
- Phillips SN, Benedict JW, Weimer JM, Pearce DA. CLN3, the protein associated with batten disease: structure, function and localization. J Neurosci Res. 2005;79:573–83. - PubMed
-
- Adams H, de Blieck EA, Mink JW, Marshall FJ, Kwon J, Dure L, et al. Standardized assessment of behavior and adaptive living skills in juvenile neuronal ceroid lipofuscinosis. Dev Med Child Neurol. 2006;48:259–64. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources